• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
COVID-19 Testing

Does SARS-CoV-2 Infection Provide Protection Against Reinfection?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Hansen et al. (Lancet, 2021) used Denmark’s national PCR-test data from 2020 to estimate protection towards repeat infection with SARS-CoV-2

METHODS:

  • Population-level observational study
  • Data source
    • Danish Microbiology Database
    • Includes individual-level data on patients who had been tested for SARS-CoV-2 in 2020  
  • Participants
    • People tested for SARS-CoV-2 | PCR tests done on symptomatic individuals by referral within the national health-care system and parallel national testing system non-symptomatic individuals
    • Exclusion: Individuals with first positive test between the two surges, and those who died before the second surge
  • Exposures
    • Previous confirmed infection
  • Study design
    • The authors analyzed reinfection rates during the second surge of COVID-19
      • First surge: March to May, 2020
      • Second surge: September to December, 2020
    • Alternative cohort analysis: Infection rates throughout the year between those with vs without a previous confirmed infection at least 3 months earlier
    • Differences related to age, sex, and time since infection were also assessed
  • Primary outcome
    • Protection against repeat infection (1-rate ratio [RR])

RESULTS:

  • 525,339 people were tested during the first surge and eligible for follow-up in second surge
    • PCR positive: 2.11% (n=11,068)
  • Second surge positivity
    • Tested positive during first surge and positive again in second surge
      • 0.65% (95% CI, 0.51 to 0.82)
    • Tested negative during first surge, and positive in second surge
      • 3.27% (95% CI, 3.22 to 2.32)
    • Adjusted RR: 0.195 (95% CI, 0.155 to 0.246)
    • Protection against repeat infection: 80.5% (95% CI, 75.4 to 84.5)
  • Alternative cohort analysis provided similar estimates
    • Adjusted RR for reinfection: 0.212 (95% CI, 0.179 to 0.251)
    • Estimated protection: 78.8% (95% CI, 74.9 to 82.1)
  • ≥65 years
    • Observed protection against repeat infection was lower vs general population: 47.1% (95% CI, 24.7 to 62.8)
  • No difference in estimated protection against repeat infection by sex
    • Male 78.4% (95% CI, 72.1 to 83.2)
    • Female 79.1% (95% CI, 73.9 to 83.3)
  • There was also no evidence of waning protection over time
    • 3–6 months follow-up: 79.3% (95% CI, 74.4 to 83.3)
    • ≥7 months follow-up: 77.7% (95% CI, 70.9 to 82.9)

CONCLUSION:

  • In the general population, protection against repeat SARS-CoV-2 infection was approximately 80%
  • Protection was lower for ≥65 at approximately 47%
  • Protection did not wane over 2020
  • The authors conclude that while protection was “robust” overall, reduced protection in those 65 and older

…highlights the need to implement protective measures for the older population in the form of effective vaccines and enhanced physical distancing and infection control, even in those known to be previously infected

Furthermore, our data indicate that vaccination of previously infected individuals should be done because natural protection cannot be relied on

Learn More – Primary Sources:

Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study

Get COVID-19 Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 Testing Posts
Next >

Related ObG Topics:

How Long Does It Take for COVID-19 Patients to Develop Antibodies?
How Common is SARS-CoV-2 Reinfection among Healthcare Workers with Antibodies?
SARS-CoV-2 Antibody Levels in Healthcare Personnel Decreased Over 60 Days

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site